BLOG

Fierce-Biotech

Nirogy Therapeutics emerges with $16.5M to target metabolite transporters

After years working under the radar, Nirogy Therapeutics is officially launching with $16.5 million and a mission to drug a family of membrane proteins called solute carriers. The proceeds will see the company’s lead cancer program through phase 1, CEO Vincent Sandanayaka, Ph.D., said.